Univariate analysis of potential factors affecting recovery of CMV-specific CD4+ and CD8+ activity at 3 months after transplantation
. | CD4+ Th function . | . | . | CD8+ CTL function . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Factors . | Present (%) . | Absent (%) . | P . | Present (%) . | Absent (%) . | P . | ||||
| Total, n | 92 (47.7) | 101 (52.3) | NA | 29 (47.5) | 32 (52.5) | NA | ||||
| Source of stem cells | .10 | .005 | ||||||||
| Bone marrow | 73 (45.1) | 89 (54.9) | 20 (39.2) | 31 (60.8) | ||||||
| PBSCs | 19 (61.3) | 12 (38.7) | 9 (90.0) | 1 (10.0) | ||||||
| Age, y, median | 41 | 39 | .18 | 39 | 37 | .83 | ||||
| Sex | .98 | .26 | ||||||||
| Male | 53 (47.8) | 58 (52.3) | 14 (41.2) | 20 (58.8) | ||||||
| Female | 39 (47.6) | 43 (52.4) | 15 (55.6) | 12 (44.4) | ||||||
| Donor CMV serology | .99 | .60 | ||||||||
| Positive | 61 (47.7) | 67 (52.3) | 20 (45.5) | 24 (54.6) | ||||||
| Negative | 31 (47.7) | 34 (52.3) | 9 (52.9) | 8 (47.1) | ||||||
| GVHD grade | .002 | .17 | ||||||||
| 0-I | 38 (64.4) | 21 (35.6) | 12 (60.0) | 8 (40.0) | ||||||
| At least II | 54 (40.3) | 80 (59.7) | 17 (41.5) | 24 (58.5) | ||||||
| Total body irradiation | .04 | .95 | ||||||||
| Yes | 41 (40.6) | 60 (59.4) | 12 (48.0) | 13 (52.0) | ||||||
| None | 51 (55.4) | 41 (44.6) | 17 (47.2) | 19 (52.8) | ||||||
| Prior ganciclovir use* | .08 | .50 | ||||||||
| Yes | 66 (44.3) | 83 (55.7) | 23 (45.1) | 28 (54.9) | ||||||
| No | 26 (59.1) | 18 (40.9) | 6 (60.0) | 4 (40.0) | ||||||
| HLA status | < .0001 | .05 | ||||||||
| MR | 76 (60.8) | 49 (39.2) | 26 (54.2) | 22 (45.8) | ||||||
| MMR/URD | 16 (23.5) | 52 (76.5) | 3 (23.1) | 10 (76.9) | ||||||
| ATG† | .009 | .99 | ||||||||
| Yes | 4 (20.0) | 16 (80.0) | 2 (50.0) | 2 (50.0) | ||||||
| No | 88 (50.9) | 85 (49.1) | 27 (47.4) | 30 (52.6) | ||||||
| Corticosteroid use‡ | < .0001 | .002 | ||||||||
| 0 | 54 (74.0) | 19 (26.0) | 18 (62.1) | 11 (37.9) | ||||||
| Between 0 and 1 | 35 (57.4) | 26 (42.6) | 11 (50.0) | 11 (50.0) | ||||||
| At least 2 | 1 (1.8) | 56 (98.3) | 0 (0.0) | 10 (100.0) | ||||||
| CD4 count at 3 mo | .0003 | .12 | ||||||||
| At least 100/mm3 | 22 (62.9) | 13 (37.1) | 6 (50.0) | 6 (50.0) | ||||||
| Less than 100/mm3 | 23 (27.7) | 60 (72.3) | 4 (20.0) | 16 (80.0) | ||||||
| CD8 count at 3 mo | ||||||||||
| At least 100/mm3 | 24 (51.1) | 23 (48.9) | .02 | 6 (46.2) | 7 (53.9) | .24 | ||||
| Less than 100/mm3 | 21 (29.2) | 51 (70.8) | 4 (21.1) | 15 (79.0) | ||||||
| At least 50/mm3 | NA | NA | NA | 10 (41.7) | 14 (58.3) | .04 | ||||
| Less than 50/mm3 | NA | NA | 0 (0.0) | 8 (100.0) | ||||||
. | CD4+ Th function . | . | . | CD8+ CTL function . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Factors . | Present (%) . | Absent (%) . | P . | Present (%) . | Absent (%) . | P . | ||||
| Total, n | 92 (47.7) | 101 (52.3) | NA | 29 (47.5) | 32 (52.5) | NA | ||||
| Source of stem cells | .10 | .005 | ||||||||
| Bone marrow | 73 (45.1) | 89 (54.9) | 20 (39.2) | 31 (60.8) | ||||||
| PBSCs | 19 (61.3) | 12 (38.7) | 9 (90.0) | 1 (10.0) | ||||||
| Age, y, median | 41 | 39 | .18 | 39 | 37 | .83 | ||||
| Sex | .98 | .26 | ||||||||
| Male | 53 (47.8) | 58 (52.3) | 14 (41.2) | 20 (58.8) | ||||||
| Female | 39 (47.6) | 43 (52.4) | 15 (55.6) | 12 (44.4) | ||||||
| Donor CMV serology | .99 | .60 | ||||||||
| Positive | 61 (47.7) | 67 (52.3) | 20 (45.5) | 24 (54.6) | ||||||
| Negative | 31 (47.7) | 34 (52.3) | 9 (52.9) | 8 (47.1) | ||||||
| GVHD grade | .002 | .17 | ||||||||
| 0-I | 38 (64.4) | 21 (35.6) | 12 (60.0) | 8 (40.0) | ||||||
| At least II | 54 (40.3) | 80 (59.7) | 17 (41.5) | 24 (58.5) | ||||||
| Total body irradiation | .04 | .95 | ||||||||
| Yes | 41 (40.6) | 60 (59.4) | 12 (48.0) | 13 (52.0) | ||||||
| None | 51 (55.4) | 41 (44.6) | 17 (47.2) | 19 (52.8) | ||||||
| Prior ganciclovir use* | .08 | .50 | ||||||||
| Yes | 66 (44.3) | 83 (55.7) | 23 (45.1) | 28 (54.9) | ||||||
| No | 26 (59.1) | 18 (40.9) | 6 (60.0) | 4 (40.0) | ||||||
| HLA status | < .0001 | .05 | ||||||||
| MR | 76 (60.8) | 49 (39.2) | 26 (54.2) | 22 (45.8) | ||||||
| MMR/URD | 16 (23.5) | 52 (76.5) | 3 (23.1) | 10 (76.9) | ||||||
| ATG† | .009 | .99 | ||||||||
| Yes | 4 (20.0) | 16 (80.0) | 2 (50.0) | 2 (50.0) | ||||||
| No | 88 (50.9) | 85 (49.1) | 27 (47.4) | 30 (52.6) | ||||||
| Corticosteroid use‡ | < .0001 | .002 | ||||||||
| 0 | 54 (74.0) | 19 (26.0) | 18 (62.1) | 11 (37.9) | ||||||
| Between 0 and 1 | 35 (57.4) | 26 (42.6) | 11 (50.0) | 11 (50.0) | ||||||
| At least 2 | 1 (1.8) | 56 (98.3) | 0 (0.0) | 10 (100.0) | ||||||
| CD4 count at 3 mo | .0003 | .12 | ||||||||
| At least 100/mm3 | 22 (62.9) | 13 (37.1) | 6 (50.0) | 6 (50.0) | ||||||
| Less than 100/mm3 | 23 (27.7) | 60 (72.3) | 4 (20.0) | 16 (80.0) | ||||||
| CD8 count at 3 mo | ||||||||||
| At least 100/mm3 | 24 (51.1) | 23 (48.9) | .02 | 6 (46.2) | 7 (53.9) | .24 | ||||
| Less than 100/mm3 | 21 (29.2) | 51 (70.8) | 4 (21.1) | 15 (79.0) | ||||||
| At least 50/mm3 | NA | NA | NA | 10 (41.7) | 14 (58.3) | .04 | ||||
| Less than 50/mm3 | NA | NA | 0 (0.0) | 8 (100.0) | ||||||
Units per mm3 equal × 109/L. NA indicates not applicable; MR, major HLA-matched, related transplant; MMR, mismatched related transplant; and URD, unrelated donor transplant.
Any (ie, prophylactic or pre-emptive) use of ganciclovir before day 80.
Dose of 10 mg/kg given as part of the conditioning regimen.
Divided into 0, > 0 to ≤ 1, or 2 mg/kg/d based on maximum dose within 14 days of collection of sample for CMV CTL and LPR assays. P value based on test for trend. Data were not available for a total of 4 patients.